Moribund Poniard outlicenses focal adhesion kinase (FAK) before merger with Allozyne
This article was originally published in Scrip
Executive Summary
Poniard Pharmaceuticals, which is hoping to provide a way out for shareholders and complete a merger with privately held Allozyne before the end of 2011, has granted an undisclosed party the worldwide rights to its focal adhesion kinase (FAK) technology, including a preclinical candidate that is a selective small molecule inhibitor of FAK.